AbbVie jumps into CD47 game, engineers $3B deal with ambitious Chinese player
Gilead’s $4.9 billion bet on Forty Seven evidently triggered a rush among Big Pharma to look for their own drug that targets the CD47 “don’t-eat-me” signal. AbbVie has now jumped on the bandwagon, paying $180 million upfront to license an antibody out of China.
I-Mab is keeping China rights to lemzoparlimab, which chairman Jingwu Zang says distinguishes itself by minimizing binding to red blood cells and therefore avoiding side effects such as anemia.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.